Last reviewed · How we verify
low-dose epinephrine and tranexamic acid
Low-dose epinephrine stimulates adrenergic receptors to increase heart rate and blood pressure, while tranexamic acid inhibits fibrinolysis to reduce bleeding.
Low-dose epinephrine stimulates adrenergic receptors to increase heart rate and blood pressure, while tranexamic acid inhibits fibrinolysis to reduce bleeding. Used for Acute hemorrhage and hemorrhagic shock, Trauma-related bleeding.
At a glance
| Generic name | low-dose epinephrine and tranexamic acid |
|---|---|
| Sponsor | King Abdullah International Medical Research Center |
| Drug class | Combination hemostatic and vasopressor agent |
| Target | Alpha-1 and beta-1 adrenergic receptors (epinephrine); plasminogen and plasmin (tranexamic acid) |
| Modality | Small molecule |
| Therapeutic area | Trauma, Hemorrhage, Critical Care |
| Phase | FDA-approved |
Mechanism of action
This combination leverages epinephrine's sympathomimetic effects to support cardiovascular function and perfusion, particularly in hemorrhagic or shock states. Tranexamic acid works by inhibiting plasminogen activation and plasmin activity, thereby stabilizing clot formation and reducing fibrin degradation. Together, they address both hemodynamic instability and excessive bleeding.
Approved indications
- Acute hemorrhage and hemorrhagic shock
- Trauma-related bleeding
Common side effects
- Tachycardia
- Hypertension
- Arrhythmias
- Thrombotic events
- Nausea
Key clinical trials
- The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery (PHASE4)
- The Effects of Low-dose Epinephrine Plus Tranexamic Acid on Perioperative Haemostasis and Inflammatory Reaction in Major Surgery (NA)
- Intravenous Versus Topical Administration of Low Dose Epinephrine Plus Combined Administration of Intravenous and Topical Tranexamic Acid (TXA)for Primary Total Knee Arthroplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: